CryoCase: Rethink the standard. Replace the bag.

What is the CellSeal® CryoCase™ for Cell and Gene Therapy Storage?

BioLife Solutions' CellSeal® CryoCase™ officially launched on November 18, 2024, and is available now for purchase for laboratory use, or for testing and evaluation. The CellSeal CryoCase, for cell and gene therapy (CGT) storage, is the first rigid primary container engineered for closed-system, fill and retrieval of larger volumes of fluid (<75 mL). The CryoCase was specifically designed for CGT developers. In this blog post, we highlight the key benefits of the CryoCase compared to traditional storage containers and share data we have compiled internally and externally in partnership with multiple CGT-focused organizations.

CryoCase advantages over traditional containers

Traditional life science, blood processing and pharmaceutical storage containers have dominated the industry for years with little innovation. CryoCase provides the CGT industry with true, closed-system fluid processing and demonstrates functional advantages to existing containers such as cryobags and cryovials.

Fracture Resistant

• The main storage area of the CryoCase has not been found to compromise the sample contents when dropped.
• CryoCase is designed to protect the main storage area from external forces, even if the outer borders are damaged.
  
  

Transparent

• CryoCase is see-through, allowing easier inspection to spot particulates and other contaminants.
• Transparency makes it easier to distinguish bubbles vs. true contaminants.
  
  

Automation Ready

• CryoCase reduces the number of operators needed and the time it takes to complete a fill in an automated manufacturing fill and finish step.
• An air evacuation step is not required, as it is with cryobags.
  
  

Equivalent Performance

• CryoCase has similar performance in freeze-down and post-thaw in cell density, cell recovery and cell viability percentages.
  
  

Why should I try something new?

In-house data shows a high percentage of cryobags are rejected due to particulate contamination, and are fractured after freezing, transport or right before thawing. CryoCase lessens these issues, which have significant time and cost savings to manufacturing. Less product will be discarded from contamination or from being shattered. Review our internal testing data and analyses from third-party CGT organizations below to see how CryoCase can make a difference in your cell processing workflow.

White Papers:

Cell & Gene Therapy Insights: Cryopreserving CAR-T cells in a novel, rigid container maintains their phenotype and function compared to conventional cryobags and cryovials

Cell & Gene Therapy Insights: Can primary packaging selection help mitigate particulate risks in cell and gene therapy manufacturing?

Webinars:

Nature Portfolio + Charles River Laboratories, August 2024

Cell & Gene Therapy Insights, April 2024

ISCT (International Society for Cell & Gene Therapy) Posters:

Are new options needed for primary packaging?, May 2024

Novel Container for Optimal Cryostorage, May 2023

Moving Storage Container Design Forward

It's time to think deeper about your storage containers and consider alternatives that can produce comparable results. Utilizing new and innovative CGT-specific storage containers could result in better quality inspections, improved adherence to GMP or cGMP protocols and accelerate U.S. FDA or EU approval of new therapies. In the end, patients receiving life-saving treatments will benefit from less time and effort spent during the sample collection phase and from more therapies being brought to the market sooner.

Reach out to us with any questions or request your test sample >>

Public link

Please use the above public link if you want to share this noodl on another website.